Beximco Pharmaceuticals Limited
BXP.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | £1,655,272 | £859,365 | £854,106 | £1,160,424 |
| Short-Term Investments | £700,000 | £450,000 | £200,000 | £200,000 |
| Receivables | £4,625,877 | £6,769,740 | £6,453,514 | £3,758,675 |
| Inventory | £15,098,238 | £14,145,102 | £13,014,795 | £13,531,933 |
| Other Curr. Assets | £2,552,595 | £309,654 | £295,170 | £2,791,486 |
| Total Curr. Assets | £24,631,982 | £22,533,861 | £20,817,584 | £21,813,645 |
| Property Plant & Equip (Net) | £43,694,292 | £42,928,597 | £43,049,308 | £42,903,938 |
| Goodwill | £674,570 | £674,570 | £674,570 | £674,570 |
| Intangibles | £4,722,487 | £4,685,005 | £4,720,697 | £4,748,985 |
| Long-Term Investments | -£679,026 | -£429,027 | -£179,027 | -£179,027 |
| Tax Assets | £57,875 | £55,106 | £60,891 | £200,000 |
| Other NC Assets | £700,000 | £450,000 | £200,000 | £61,183 |
| Total NC Assets | £49,170,198 | £48,364,251 | £48,526,439 | £48,409,649 |
| Other Assets | £0 | £0 | £0 | £0 |
| Total Assets | £73,802,180 | £70,898,112 | £69,344,023 | £70,223,294 |
| Liabilities | – | – | – | – |
| Payables | £3,302,940 | £3,904,271 | £3,671,372 | £4,549,964 |
| Short-Term Debt | £4,168,790 | £2,093,299 | £3,135,956 | £5,824,152 |
| Tax Payable | £828,950 | £664,193 | £429,267 | £620,775 |
| Deferred Revenue | £0 | £0 | £0 | £0 |
| Other Curr. Liab. | £3,238,602 | £2,593,648 | £2,325,392 | £1,147,200 |
| Total Curr. Liab. | £11,539,282 | £9,255,411 | £9,561,986 | £12,142,091 |
| LT Debt | £2,024,509 | £0 | £1,757,971 | £1,603,815 |
| Deferred Rev, NC | £0 | £0 | £0 | £0 |
| Deferred Tax Liab, NC | £2,563,616 | £2,570,422 | £2,574,582 | £0 |
| Other NC Liab. | £4,045,810 | £5,477,245 | £3,546,580 | £6,066,811 |
| Total NC Liab. | £8,633,935 | £8,047,667 | £7,879,133 | £7,670,626 |
| Other Liabilities | £0 | £0 | £0 | £0 |
| Cap. Leases | £383,165 | £0 | £464,015 | £482,025 |
| Total Liabilities | £20,173,217 | £17,303,078 | £17,441,120 | £19,812,717 |
| Equity | – | – | – | – |
| Pref Stock | £0 | £0 | £0 | £0 |
| Common Stock | £4,461,121 | £4,461,121 | £4,461,121 | £4,461,121 |
| Retained Earnings | £36,807,477 | £36,761,005 | £35,079,327 | £33,599,450 |
| AOCI | £1,448,689 | £1,449,546 | £1,450,405 | £1,451,373 |
| Other Equity | £6,959,112 | £6,959,112 | £6,959,112 | £6,959,112 |
| Total Equity | £49,676,399 | £49,630,784 | £47,949,965 | £46,471,056 |
| Supplemental Information | – | – | – | – |
| Minority Interest | £3,952,564 | £3,964,250 | £3,952,938 | £3,939,521 |
| Total Liab. & Tot. Equity | £73,802,180 | £70,898,112 | £69,344,023 | £70,223,294 |
| Net Debt | £4,538,027 | £1,233,934 | £4,039,821 | £6,267,543 |